Australia's ImpediMed rises on extending contract with AstraZeneca
18/03/2022 05:00
** Shares of ImpediMed Ltd IPD.AX climb as much as 5.2% to
A$0.153, their best session since Feb. 25
** Says British pharmeceutical co AstraZeneca AZN.L has
extended its contract to use IPD's SOZO Digital Health Platform
for clinical trials urn:newsml:reuters.com:*:nASX393LM5
** SOZO devices will be used to track patient fluid volume
in an upcoming pharmaceutical study by AZN focused on chronic
kidney disease
** Has signed over A$5.5 million in contract value under the
various AstraZeneca trial agreements
** AZN also increased the number of SOZO devices required by
23, taking the total number in the trial to 223
** IPD hits highest level since March 10
** IPD down 17.1% YTD, as of last close
(Reporting by Harshita Swaminathan in Bengaluru)
((Harshita.Swaminathan@thomsonreuters.com))